Gene expression profile in relapsed or metastatic HNSCC patients treated with cetuximab and platinum therapy

ABSTRACT: First line chemotherapy with platinum and cetuximab is usually offered to RM-HNSCC pts. In the Extreme trial a median progression free survival (PFS) time of 5.6 months was reported. However, a small fraction of pts achieves a prolonged PFS (> than 12 months). Till now, no recognized predictive biological factor has been identified. A group of 14 cases treated with a first line platinum and cetuximab with a PFS exceeding 12 months (long PFS) and a group of 26 pts with a PFS less than 5.6 months (short PFS) were selected. The 2 groups were well balanced in regard to recognized prognostic factors (performance status, weight loss, prior radiotherapy, tumor grade, site of primary tumor, residual disease at primary tumor site). Tumor specimens of the recurrence or, if not available, of the pr

ORGANISM(S): Homo sapiens

SUBMITTER: Loris De Cecco 

PROVIDER: E-GEOD-65021 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress